The Early Response to Dietary Therapy can Predict the Late Outcome in Children with Intractable Epilepsy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Dietary therapy (DT), including the ketogenic diet (KD), is one of the nonpharmacological treatment options for patient with drug-resistant epilepsy. However, maintaining DT in patients without seizure reduction is very difficult, so it is critical for clinicians to decide when to stop this intervention. Methods We retrospectively analyzed early clinical and laboratory findings and the clinical characteristics of children who received DT. The maintenance of DT and the clinical seizure frequency were assessed at 1, 3, 6, 12, and 24 months after KD initiation. Responders were defined as patients showing an overall reduction in seizure frequency of >50% relative to the baseline. Results We included 67 patients who received DT, but only 23 (34.3%) of these patients remained on DT at 6 months. Only 1 (5%) of the 20 responders at 1 month became a nonresponder at 6 months. The response rate at 6 months was significantly higher among patients under 2 years of age (15/17, 88.2%) than older patients (2/6, 33.3%; p=0.021). Moreover, the 6-month responders were significantly younger (29.4±38.6 months, mean±SD) than the nonresponders (98.9±84.6 months, p=0.012) at the initiation of the diet. A high blood β-hydroxybutyrate (BHB) level at 1 month predicted a good DT response at 6 months. Conclusions Most 1-month responders maintained their response on DT for up to 6 months. The blood BHB level at 1 month was significantly correlated with the 6-month seizure outcome. Confirming clinical and laboratory biomarkers for the efficacy of DT requires further studies with larger cohorts.
Abstract
Background and Purpose Dietary therapy (DT), including the ketogenic diet (KD), is one of the nonpharmacological treatment options for patient with drug-resistant epilepsy. However, maintaining DT in patients without seizure reduction is very difficult, so it is critical for clinicians to decide when to stop this intervention. Methods We retrospectively analyzed early clinical and laboratory findings and the clinical characteristics of children who received DT. The maintenance of DT and the clinical seizure frequency were assessed at 1, 3, 6, 12, and 24 months after KD initiation. Responders were defined as patients showing an overall reduction in seizure frequency of >50% relative to the baseline. Results We included 67 patients who received DT, but only 23 (34.3%) of these patients remained on DT at 6 months. Only 1 (5%) of the 20 responders at 1 month became a nonresponder at 6 months. The response rate at 6 months was significantly higher among patients under 2 years of age (15/17, 88.2%) than older patients (2/6, 33.3%; p=0.021). Moreover, the 6-month responders were significantly younger (29.4±38.6 months, mean±SD) than the nonresponders (98.9±84.6 months, p=0.012) at the initiation of the diet. A high blood β-hydroxybutyrate (BHB) level at 1 month predicted a good DT response at 6 months. Conclusions Most 1-month responders maintained their response on DT for up to 6 months. The blood BHB level at 1 month was significantly correlated with the 6-month seizure outcome. Confirming clinical and laboratory biomarkers for the efficacy of DT requires further studies with larger cohorts.
참고문헌 (18)
- Kwan P, "Definition of drug resistant epilepsy : consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies", Epilepsia, 51, pp.1069~1077 (2010)
- Hao XT, "Interrater reliability of the international consensus definition of drug-resistant epilepsy : a pilot study", Epilepsy Behav, 22, pp.388~390 (2011)
- Wheless JW, "History of the ketogenic diet", Epilepsia, 49(Suppl 8), pp.3~5 (2008)
- Kossoff EH, "A modified Atkins diet is effective for the treatment of intractable pediatric epilepsy", Epilepsia, 47, pp.421~424 (2006)
- Pfeifer HH, "Low-glycemic-index treatment : a liberalized ketogenic diet for treatment of intractable epilepsy", Neurology, 65, pp.1810~1812 (2005)
- Boison D, "New insights into the mechanisms of the ketogenic diet", Curr Opin Neurol, 30, pp.187~192 (2017)
- Seo JH, "Efficacy and tolerability of the ketogenic diet according to lipid : nonlipid ratios--comparison of 3 : 1 with 4 : 1 diet", Epilepsia, 48, pp.801~805 (2007)
- Sourbron J, "Ketogenic diet for the treatment of pediatric epilepsy : review and meta-analysis", Childs Nerv Syst, 36, pp.1099~1109 (2020)
- Martin K, "Ketogenic diet and other dietary treatments for epilepsy", Cochrane Database Syst Rev, 2, pp.CD001903~ (2016)
- van Delft R, "Blood beta-hydroxybutyrate correlates better with seizure reduction due to ketogenic diet than do ketones in the urine", Seizure, 19, pp.36~39 (2010)
- Berg AT, "Revised terminology and concepts for organization of seizures and epilepsies : report of the ILAE Commission on Classification and Terminology, 2005-2009", Epilepsia, 51, pp.676~685 (2010)
- Baby N, "A pragmatic study on efficacy, tolerability and long term acceptance of ketogenic diet therapy in 74 South Indian children with pharmacoresistant epilepsy", Seizure, 58, pp.41~46 (2018)
- Freeman JM, "The efficacy of the ketogenic diet-1998 : a prospective evaluation of intervention in 150 children", Pediatrics, 102, pp.1358~1363 (1998)
- Jagadish S, "The ketogenic and modified Atkins diet therapy for children with refractory epilepsy of genetic etiology", Pediatr Neurol, 94, pp.32~37 (2019)
- Kossoff EH, "Efficacy of the ketogenic diet for infantile spasms", Pediatrics, 109, pp.780~783 (2002)
- Nordli DR Jr, "Experience with the ketogenic diet in infants", Pediatrics, 108, pp.129~133 (2001)
- Rezaei S, "Short-term and long-term efficacy of classical ketogenic diet and modified Atkins diet in children and adolescents with epilepsy : a systematic review and meta-analysis", Nutr Neurosci, 22, pp.317~334 (2019)
- Kossoff EH, "A decade of the modified Atkins diet(2003–2013) : results, insights, and future directions", Epilepsy Behav, 29, pp.437~442 (2013)